Matthew Ronsheim, PhD, Appointed COO for Xenon Pharmaceuticals

Neuroscience biopharmaceutical company, Xenon Pharmaceuticals, has hired Matt Ronsheim, PhD, as its Chief Operating Officer where he will oversee CMC, Program Management and Quality Assurance. We are delighted to have recruited five executives to Xenon as the company continues its evolution towards the commercialization of its first product candidate.

Dr. Ronsheim has 25 years of experience bringing important medicines from discovery through clinical development, global regulatory filings and approvals, and commercial launch and supply. Before joining Xenon, Dr. Ronsheim was President of Innoviva Specialty Therapeutics, having previously served as their Chief Technical Officer. Prior to this, Dr. Ronsheim was President of Entasis Therapeutics, which was acquired by Innoviva, Inc. in 2022. Throughout his career, he has held leadership roles overseeing research, CMC, pharmaceutical development, and commercialization at companies including Merck/Cubist Pharmaceuticals, Enanta Pharmaceuticals, and Forest Laboratories. Dr. Ronsheim’s industry contributions and leadership have contributed to delivering important therapies across several disease areas including central nervous system disorders. Dr. Ronsheim holds a BS in Chemistry from Southern Connecticut State University and a PhD in Synthetic Organic Chemistry from the University of New Hampshire.